



Western Washington University
Western CEDAR

WWU Graduate School Collection

WWU Graduate and Undergraduate Scholarship

Summer 2016

Mapping Interactions Between the Type-VI Secretion System Effector tAE1 and Its Putative Substrates Using NMR Spectroscopy

Robert C. (Robert Corey) Henderson
Western Washington University, robert.c.henderson575@gmail.com

Follow this and additional works at: <https://cedar.wwu.edu/wwuet>

 Part of the [Chemistry Commons](#)

Recommended Citation

Henderson, Robert C. (Robert Corey), "Mapping Interactions Between the Type-VI Secretion System Effector tAE1 and Its Putative Substrates Using NMR Spectroscopy" (2016). *WWU Graduate School Collection*. 521.

<https://cedar.wwu.edu/wwuet/521>

This Masters Thesis is brought to you for free and open access by the WWU Graduate and Undergraduate Scholarship at Western CEDAR. It has been accepted for inclusion in WWU Graduate School Collection by an authorized administrator of Western CEDAR. For more information, please contact westerncedar@wwu.edu.

**Mapping Interactions between the Type-VI Secretion
System Effector Tae1 and its Putative Substrates
Using NMR Spectroscopy**

By

Robert Corey Henderson

Accepted in Partial Completion
Of the Requirements for the Degree
Master of Science

Kathleen L. Kitto, Dean of the Graduate School

ADVISORY COMMITTEE

Chair, Dr. Spencer Anthony-Cahill

Dr. P. Clint Spiegel

Dr. Serge Smirnov

MASTER'S THESIS

In presenting this thesis in partial fulfillment of the requirements for a master's degree at Western Washington University, I grant to Western Washington University the non-exclusive royalty-free right to archive, reproduce, distribute, and display the thesis in any and all forms, including electronic format, via any digital library mechanisms maintained by WWU.

I represent and warrant this is my original work, and does not infringe or violate any rights of others. I warrant that I have obtained written permissions from the owner of any third party copyrighted material included in these files.

I acknowledge that I retain ownership rights to the copyright of this work, including but not limited to the right to use all or part of this work in future works, such as articles or books.

Library users are granted permission for individual, research and non-commercial reproduction of this work for educational purposes only. Any further digital posting of this document requires specific permission from the author.

Any copying or publication of this thesis for commercial purposes, or for financial gain, is not allowed without my written permission.

Signature: R. Corey Henderson

Date: 07/20/2016

**Mapping Interactions between the Type-VI Secretion
System Effector Tae1 and its Putative Substrates
Using NMR Spectroscopy**

A Thesis
Presented To
The Faculty of
Western Washington University

In Partial Fulfillment
Of the Requirements for the Degree
Master of Science

By
Robert Corey Henderson

06/29/2016

Abstract

Tae1 is an amidase produced by gram negative *Pseudomonas* bacteria that attacks the peptidoglycan layer in the cell walls of neighboring bacteria after secretion through the Type VI secretion system (T6S). The goal of our work is mapping interactions between the type-VI-secretion system effector Tae1 and its putative substrates using nuclear magnetic resonance (NMR) spectroscopy. Tae1 is amenable to NMR in that we are able to collect spectra with resolved, well defined peaks that can be assigned, thereby providing valuable structural information. We have assigned 89.2% of backbone atoms and 87.4% of sidechain atoms. Assignment of Tae1 was performed with ^{15}N -HSQC, HNCA, HNCOCA, HNCACB, CBCACONH, HCCH COSY, HCCH TOCSY, and HCONH TOCSY experiments. Peptidoglycan binding experiments were performed using via ^{15}N -HSQC to monitor backbone residues and ^{13}C -HSQC to monitor sidechain residues. So far, these experiments have not revealed the molecular mechanism by which Tae1 recognizes its specific substrate; however, with the very high degree of assignment achieved in NMR experimentation, once a minimal binding fragment has been isolated determination of the binding mechanism will be easily achieved.

Acknowledgments

I would like to express my sincere gratitude to the following individuals:

My advisor, Dr. Spencer Anthony-Cahill without whom I don't know where I would be. His knowledge and passion for biochemistry have encouraged and inspired me to push myself further than I thought possible.

My committee members, Dr. P. Clint Spiegel, and Dr. Serge Smirnov for their availability and support.

Dr. Peter Brzovic for his training and support for NMR.

Dr. Seemay Chou for her immense efforts, incredible patience, and time donated to this project.

Past and present group members for creating a positive and successful environment.

My wonderfully supportive wife Laura, who has been with me at every step; and lastly my family who have given me so much encouragement along the way.

Table of Contents

| | |
|---|-------------|
| Abstract | iv |
| Acknowledgments | v |
| List of Figures | viii |
| Introduction | 1 |
| Pathogenic bacterial resistance to antibiotics | 1 |
| Bacterial cellular envelope review | 1 |
| Peptidoglycan (PG) review | 2 |
| Impact of peptidoglycan on antibiotic research | 4 |
| Difficulties in structural investigation of peptidoglycan | 5 |
| HPLC investigation of peptidoglycan..... | 6 |
| Type six secretion amidase effector 1 (Tae1) | 7 |
| Type six secretion system (T6S) | 9 |
| Localization of effectors to T6S via Hcp1 | 11 |
| T6S amidase effector families | 13 |
| Cleavage specificity of Tae1 | 14 |
| Structure of Tae1..... | 16 |
| Nuclear Magnetic Resonance (NMR) investigation review | 17 |
| Application of NMR to Tae1 | 23 |
| Methods | 24 |
| Peptidoglycan isolation | 24 |
| NMR data collection..... | 25 |
| NMR data assignment..... | 25 |
| Results | 27 |
| Tae1 backbone NMR characterization | 27 |
| NMR investigation of Tae1 titration with Hcp1 | 31 |
| NMR investigation of Tae1 with PG fragment | 33 |
| Tae1 sidechain NMR characterization..... | 34 |
| NMR investigation of Tae1 with intact bacterial sacculi..... | 35 |
| Discussion | 35 |
| Interaction of Tae1 and Hcp1..... | 36 |

| | |
|--|-----------|
| Interaction of Tae1 with PG fragment | 35 |
| Generation of minimal binding fragment | 37 |
| Similar experimental model LytA | 38 |
| Solid state NMR investigation of PG/protein interaction | 39 |
| Works cited | 40 |
| Appendix | 44 |
| Residue assignment tables for Tae1 | 45 |
| NHSQC NMR assignment of Tae1..... | 53 |
| CHSQC NMR assignment of Tae1 | 54 |
| Graphical comparisons of Tae1 Hcp1 titration | 55 |
| Experimental design for confirmation of Tae1 binding specificity | 57 |

List of Figures

| | |
|---|----|
| Figure 1: Simplified structure of Gram +/Gram – cells. | 2 |
| Figure 2: Structure of peptidoglycan. | 3 |
| Figure 3: Structures of Beta lactam antibiotics | 4 |
| Figure 4: HPLC analysis of mucopeptide fragments after digestion with Tae4 and Tae3 as well as a control displaying all possible fragments..... | 6 |
| Figure 5: X-ray crystal structures of closest structural homologs "housekeeping" PG amidases and Tae1..... | 8 |
| Figure 6: Cartoon representation of type six secretion with host cell piercing outer membrane of neighboring cell and injecting toxic effects. | 9 |
| Figure 7: TEM images of Hcp1 showing the distribution of class averages in a sample of 3,000 randomly selected particles..... | 11 |
| Figure 8: The families of toxic effectors are distinguished by their peptidoglycan cleavage specificity. | 12 |
| Figure 9: Sites of PG cleavage by the distinct amidase families. | 12 |
| Figure 10: HPLC chromatograms of PG sacculus treated with the muramidase cellosyl and PG sacculus treated with Tae1 followed by cellosyl..... | 14 |
| Figure 11: Tae1 crystal structure a fragment of PG modeled in the binding cleft in one possible conformation within the active site. | 15 |
| Figure 12: Larmor precession of nuclear spins in an external magnetic field. | 16 |
| Figure 13: NMR data workflow. | 18 |
| Figure 14: 1D ¹ H-NMR spectrum of the small protein ubiquitin. | 19 |
| Figure 15: Display of a 2D Protein NMR experiment. | 20 |
| Figure 16: 2D NMR top down "topographical" map view of a standard NHSQC. | 21 |

| | |
|--|----|
| Figure 17: Pymol image of Tae1 with assigned backbone residues colored in green, and unassigned residues colored in grey..... | 27 |
| Figure 18: Pymol image of the backside of Tae1 with assigned backbone residues colored in green, and unassigned residues colored in grey. | 28 |
| Figure 19: Pymol image of Tae1 with assigned side chain residues colored in green, and unassigned residues colored in grey..... | 29 |
| Figure 20: Pymol image of the backside of Tae1 with assigned side chain residues colored in green, and unassigned residues colored in grey | 30 |
| Figure 21: NHSQC overlay of Tae1 titration with Hcp1. | 31 |
| Figure 22: Representative panels from NHSQC titration of Tae1 with increasing concentrations of Hcp1..... | 31 |
| Figure 23: Representative panels from NHSQC titration of Tae1 with increasing concentration of Hcp1 mutant S115Q..... | 32 |
| Figure 24: NHSQC overlay of Tae1 and Tae1 incubated with tetra-tetra fragment of PG. | 33 |
| Figure 25: CHSQC of Tae1 | 33 |
| Figure 26: CHSQC spectra of Tae1, Tae1 incubated with whole sacculi, and Tae1 incubated with whole sacculi then with lysozyme | 35 |
| Figure 27: Cartoon representation of minimal binding fragment generation/isolation experiment. | 37 |

With multi-drug resistant bacteria becoming more and more prevalent, we can no longer rely on well-established antibiotics to treat life-threatening bacterial infections. As pathogenic bacteria have become resistant to humanity's primary defense against them, a detailed understanding of resistance in pathogenic bacteria is an imperative. Among the most important research to be done currently is the development of new antibiotics so that resistant infections can be treated successfully (Taneja *et al.* 2016). Research regarding potential targets for novel antibiotics is focused on conserved structures unique to bacteria that are necessary for their survival. One of the most conserved and critical structures ubiquitous throughout the bacterial kingdom is the bacterial cell wall (Kuhner *et al.* 2014).

The bacterial cellular envelope is composed of the plasma membrane and the cell wall; it is the bacterium's first line of defense against threats it encounters in its environment. The bacterial envelope was viewed until the 1950's as a simple self-assembling semipermeable sack around the cell (Silhavy *et al.* 2010). We now know that the bacterial cellular envelope is a complex and varied structure that requires a significant investment of energy to assemble and maintain (Brown *et al.* 2013).

The cellular envelope must protect the bacterium from its hostile and often rapidly changing environment, while still allowing selective transport of nutrients into the cytosol (Silhavy *et al.* 2010). Investigation into the bacterial cellular envelope led to the development of the famous Gram staining technique (Taneja *et al.* 2016). There are two major classes of bacterial cellular envelopes characterized by the Gram stain: gram

positive, and gram negative (Figure 1). Gram positive bacteria such as *S. aureus* have an inner membrane surrounded by a thick layer of peptidoglycan (PG) composing the bacterial cell wall. In contrast, gram negative bacteria, such as *E. coli*, have a much thinner peptidoglycan cell wall but a second protective membrane outside of the peptidoglycan layer (Gan *et al.* 2008). The entire PG layer with the proteins and remaining cellular components removed is known as the bacterial sacculus. The sacculus is a gigadalton-large, highly dynamic, heterogeneous structure, which has proven difficult to characterize structurally (Schanda *et al.* 2014). While the composition of the peptidoglycan wall is well-characterized through electron cryotomography and atomic-force microscopy, protein-peptidoglycan, and peptidoglycan interaction with antibiotics have been difficult to elucidate (Schanda *et al.* 2014).

[Simplified structure of Gram+/Gram- Cellular Envelopes](http://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/peptidoglycans.html)

Figure 1: Simplified structure of Gram +/Gram – cells. Image Available at: <http://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/peptidoglycans.html>.

The peptidoglycan cell wall is the prokaryotic cell's molecular coat of armor. As shown in Figure 2, it is a rigid structure with a backbone composed of repeating alternating units of the monosaccharides N-acetyl glucosamine (GlcNAc) and N-acetyl muramic acid (MurNAc) with a network of cross-linked peptides extending from the glycan backbone (Gan *et al.* 2008). Positions of the crosslinks can vary among bacterial

species but in general are conserved within a particular species (Silhavy *et al.* 2010). The rigid peptidoglycan cell wall makes up a single macromolecule surrounding the cell (Romaniuk *et al.* 2015). The cell wall provides structural support for the cell, creates the characteristic shapes of many bacteria, and confers resistance to turgor pressure (Chou *et al.* 2012). That prokaryotic cells do not lyse in a dilute solution such as distilled water is mediated, in the greatest part, by the peptidoglycan cell wall (Silhavy *et al.* 2010).

[Molecular structure of peptidoglycan](#)

Figure 2: Structure of peptidoglycan. Image modified from American Society for Microbiology. Original available at: <http://cmr.asm.org/content/18/3/521/F2.expansion.html>. Accessed October 18, 2014.

As the cell wall is rigid, a cell must break down and reform the peptidoglycan for growth and division. The maintenance of the peptidoglycan cell wall is an energy intensive process. Formation is a multistep mechanism where pentapeptide precursors are formed within the cytosol, and must be exported to the outside of the cell (Gan *et al.* 2008). These precursors are generally excreted at a small inlet of the cell wall known as the septum (Typas *et al.* 2012). Once they are excreted they are covalently bound to the GlcNAc/MurNAc by specific enzymes. Maintenance, in terms of peptidoglycan breakdown is a process which is carried out by a host of “housekeeping enzymes” (Chou *et al.* 2012). Among these housekeeping enzymes are amidases which catalyze the breakdown of peptidoglycan, and penicillin binding proteins which are necessary for catalyzing the cross-linking of new peptidoglycan (Chou *et al.* 2012).

Because PG is only observed in prokaryotes it makes a desirable target with reduced risk to eukaryotic cells. Many of modern medicine's frontline antibiotics already target PG (Kuner *et al.* 2014). For instance, penicillin targets one of the proteins responsible for the maintenance of the peptidoglycan layer (Otero *et al.* 2013). Penicillin and its derivatives like methicillin are known as β -lactam antibiotics due to their bicyclic ring structure, as shown in Figure 3, and inhibit one of the proteins which reforms the peptidoglycan known as penicillin binding protein (Otero *et al.* 2013). When the cell can no longer maintain its cell wall it will lyse and die.




Figure 3: Structures of Beta lactam antibiotics

Within the last 60 years the detailed analysis of the structure of PG has been attempted by various methods (Kühner *et al.* 2014). Because of peptidoglycan's immense size and inherent flexibility, PG does not crystallize for X-ray diffraction

imaging methods, and is only amenable to NMR solution-state experiments with muropeptide fragments or solid-state NMR investigation (Desmarais *et al.* 2014; Schanda *et al.* 2014). To date the most effective methods of probing PG structure have been the application of liquid chromatography to analyze muropeptide fragments, and electron microscopy of whole sacculi (Kühner *et al.* 2014). These techniques are limited to providing information on bulk PG structure, and crosslinking of the peptides. They cannot provide atomic-level detail to protein/PG interactions (Schanda *et al.* 2014).

High pressure liquid chromatography and ultra-pressure liquid chromatography (HPLC/UPLC) methods carried out on muropeptides has proven useful in characterizing the structure of peptidoglycan crosslinks (Desmarais *et al.* 2014). Muropeptides are fragments of peptidoglycan consisting of peptides of various lengths bound to N-acetylmuramic acid generated from enzymatic digestion of the PG into disaccharides (Kühner *et al.* 2014). As they are a substantially smaller size than the intact bacterial sacculi they can also be utilized in experimental investigations of substrate binding to PG-modifying enzymes (Kuhner *et al.* 2014).




Figure 4: HPLC analysis of muropeptide fragments after digestion with *Tae4* and *Tae3* as well as a control displaying all possible fragments. See “Figure 4a” Russell *et al.*, 2012, “A Widespread Bacterial Type VI Secretion Effector Superfamily Identified Using a Heuristic Approach;” *Cell Host and Microbe* 11: 538–549.

Substrate cleavage specificity studies are performed by treating intact bacterial sacculi with the enzyme of interest, and subsequently treating the resulting reaction mixture with an enzyme to digest (and thereby remove) the glycan strand. The remaining peptide fragments are then analyzed by HPLC/UPLC (Figure 4) to elucidate the site at which the enzyme of study is cleaving the PG (Kuhner *et al.* 2014). If no PG cleavage is performed by the enzyme of interest one would observe PG fragments of the same distribution as simply treating with lysozyme or muramidase. Furthermore, if the PG degrading enzyme of interest is promiscuous in its cleavage one would observe a broad distribution of muropeptide fragments. Thus, observing reproducible distributions of muropeptide fragments following double-digestion leads directly to the

identification of characteristic cleavage sites for the PG hydrolase of interest. While co-crystallization of proteins, with their cognate substrate is the most definitive method for determining protein substrate interactions, no structures of this class of amidase bound to substrate have been reported. Because co-crystallization has proven difficult, *in silico* docking methods have been utilized to propose potential protein/PG interactions (Chou *et al.* 2012). Thus, mucopeptides have proven to be of limited use for binding assays (Mellroth *et al.* 2014).

Our long-term goal is to elucidate the molecular details of PG binding by PG amidases, and thereby contribute to the understanding of the antibiotic action of this class of enzymes. The current work was carried out on the toxic amidase effector 1 (Tae1) from *Pseudomonas aeruginosa*. While bacterial cells employ several “housekeeping” amidases that are responsible for remodeling the PG for bacterial cell growth, they are highly regulated (to prevent toxicity) and have very closed or occluded active sites (Figure 5) making structural imaging of these enzymes with PG substrates difficult (Chou *et al.* 2012).

Pseudomonas aeruginosa engages in interbacterial “chemical warfare” using a secretion system known as Type Six Secretion (T6S) to deliver toxic effectors to neighboring bacterial cells, thereby providing it a significant competitive advantage (Russell *et al.* 2011).




Figure 5: X-ray crystal structures of closest structural homologs "housekeeping" PG amidases and Tae1. Catalytic cysteines are highlighted in yellow, and regulatory regions are highlighted in red. PDB entries 3H41, 3PBI, 2K1H, and 4F4M respectively. Note the active-site-proximal regulatory region of the non-toxic amidase YkfC (red). Further, it can be seen that RipB contains an N-terminal extension (red) and Spr has catalytic-site adjacent residues that occlude their substrate binding sites relative to that of the toxin Tae1. See "Figure 2A" from Chou et al 2012, "Structure of a Peptidoglycan Amidase Effector Targeted to Gram-Negative Bacteria by the Type VI Secretion System", *Cell Rep.* 2012; 1(6):656-64.

As shown in Figure 6, type six secretion (T6S) in *P. aeruginosa* cell requires the assembly of a long actin filament tubule akin to a bacterial sex pilus (Russell *et al.* 2011). Upon contact with a neighboring cell the tubule is rapidly shot out of the host cell piercing the neighboring cell like a hypodermic needle (Russell *et al.* 2011). A host of

toxic effectors are then injected through the T6S assembly (Russell *et al.* 2012). These toxic effectors are delivered via direct translocation through the phage-like apparatus (Russell *et al.* 2011).




Figure 6: Cartoon representation of type six secretion with host cell piercing outer membrane of neighboring cell and injecting toxic effects. See "Figure 1" from Russell, *et al.* (2014) "Type VI secretion effectors: poisons with a purpose" *Nature Rev. Microbiol.* 12: 137-148.

In addition to addressing questions of the mechanism of the effectors themselves, we hope to understand how the effectors are localized to the T6S and thereby secreted. Given the variety of proteins in the cytoplasm, how do secretion systems such as T6S discriminate between them and exclusively bind and secrete the appropriate effectors? Such substrate specificity might be mediated by several factors including signal sequences, chaperones, and receptors (Silverman *et al.* 2013).

Studies by the Mougous lab at UW Microbiology implicated the ring structured haemolysin coregulated protein 1 (Hcp1) in the localization and excretion of the type six secretion system effectors (Silverman *et al.* 2013). While initially thought of as a “static conduit” through which effectors of the T6S would pass, Hcp1 was shown to have a significant impact on both the cytoplasmic concentration of the toxic type six secretion effector 2 (Tse2) and its excretion (Silverman *et al.* 2013). To perform studies on the export of effector proteins the Δ retS mutation was incorporated which results in the excretion of effectors directly into the supernatant (Silverman *et al.* 2013). By doing this, effectors and cofactors necessary for excretion could be identified.

When Hcp1 is knocked out, the effectors Tae1, Tse2, and Tae3 are not found in the supernatant in measurable quantity (Silverman *et al.* 2013). Along with full gene knockout, structural mutations that effect the internal binding residues, such as the S115Q mutation, stop exportation of the toxic effectors (Silverman *et al.* 2013). Further investigation utilizing transmission electron microscopy (TEM) found that Tse2 was found localized and bound within the Hcp1 ring structure (Figure 7; Silverman *et al.* 2013). While it was not explicitly shown that Tae1 and Tae3 were bound within the Hcp1 ring, the secretion data cited above, and TEM findings of Tse2 bound to Hcp1 suggested that Tae1 binds with Hcp1 and is thereby exported through the T6S (Silverman *et al.* 2013). Thus, we performed NMR titration experiments with ¹⁵N-labeled Tae1 and unlabeled Hcp1 in an attempt to identify the contacts between the two proteins.




Figure 7: TEM images of Hcp1 showing the distribution of class averages in a sample of 3,000 randomly selected particles with 72% unfilled, 23% filled; additionally displayed is a control of Hcp1 not incubated with Type six secretion effector 2(Tse2), displaying that the filled particles are indeed bound with Tse2. See “Figure 3D” from Silverman *et al* 2013 “Haemolysin Coregulated Protein Is an Exported Receptor and Chaperone of Type VI Secretion Substrates,” *Annu. Rev. Microbiol.* 2012; 66: 453-72.

Tae1 and Tae3 have been shown to be lytic enzymes with Tae1 breaking down the crosslinked peptide region of the peptidoglycan and Tae3 showing muramidase activity, cleaving between the glycans in the PG backbone (Chou *et al.* 2012). These peptidoglycan hydrolases were found through a heuristic investigation to be part of a superfamily of toxic effectors which cluster into conserved branches, each with a distinct PG cleavage specificity (Figures 8 and 9; Russell *et al.* 2012).




Figure 8: Type six secretion amidase effectors can be broken into 4 family groups distinguished by their peptidoglycan cleavage specificity. See “Figure 3C” from Russell et al 2012 “A Widespread Bacterial Type VI Secretion Effector Superfamily Identified Using a Heuristic Approach,” *Cell Host Microbe*. 2012; 11(5): 538-49.




Figure 9: Sites of PG cleavage by the distinct amidase families. The color coding is the same as in Figure 8. Tips of color coded triangles point to scissile bond within the PG. See “Figure 4B” from Russell et al 2012 “A Widespread Bacterial Type VI secretion Effector Superfamily Identified Using a Heuristic Approach,” *Cell Host Microbe*. 2012; 11(5): 538-49.

The observation of conserved cleavage specificities is intriguing given their roles as toxins. More promiscuous cleavage would, in principle, inflict greater damage to the cell wall target. The PG substrates needed to determine the observed cleavage specificities are obtained from bacterial sacculi. First bacterial peptidoglycan sacculi are extracted from the rest of the bacterial cell by breaking apart the primary cell components with a bead beater, followed by sedimentation of the cell walls with high speed centrifugation, then enzymatic digestion of the remaining non-peptidoglycan elements with RNase, DNase, and Trypsin. Extracted sacculi are then treated with the given effector amidase followed by a glycan-degrading muramidase so that the remaining muropeptide fragments can be analyzed by HPLC-MS to determine where in the PG amidase directed hydrolysis occurs as seen in Figure 10 (Russell *et al.* 2012). Due to the difficulty of working with whole PG sacculi, digesting the PG macromolecule into muropeptides for further investigation is necessary for structural or binding studies (Kühner *et al.* 2014)

Tae1 was found to be specific for cleavage of the γ -D-glutamyl-L-*meso*-diaminopimelic acid (D-glu-*m-dap*) bond, indicated by the green arrowheads in Figure 10 (Chou *et al.* 2012). By the HPLC-MS experiments displayed in Figure 10 one can observe that PG fragment products obtained after double digestion of sacculi with Tae1 followed by muramidase define a high cleavage specificity of Tae1 for the D-glu-*mDap* bond. Given this cleavage specificity, *B. subtilis* was used as the bacterium of choice for the isolation sacculi to be used as a test substrate for probing the details of Tae1 binding

to PG. *B. subtilis* is a well-studied gram positive bacterium, and its PG layer contains the necessary (D-glu-*m-dap*) bond.




Figure 10: HPLC chromatograms of PG sacculus treated with the muramidase cellosyl (top) and PG sacculus treated with Tae1 followed by cellosyl (bottom). See “Figure 4A” from Chou *et al* 2012 “Structure of a Peptidoglycan Amidase Effector Targeted to Gram-Negative Bacteria by the Type VI Secretion System,” *Cell Rep.* 2012; 1(6):656-64.

The crystal structure of Tae1 has been solved to 2.6 Å resolution (Figure 11; Chou *et al.* 2012). As seen in Figure 11 the active site is very open, suggesting multiple orientations of PG are possible. Attempts to co-crystallize various PG substrates with Tae1 have not yet yielded crystals that diffract (Chou *et al.* 2012, Shang *et al.* 2012). Docking studies performed *in silico* using MacroModel 9.9 to scan the structural face of Tae1 with an L-Ala-D-Glu-mDAP PG fragment did not converge on a common bound conformation in the catalytic pocket of Tae1, but rather, returned 168 unique

conformations with 20 of them sharing the highest score from the Glide XP function (Chou *et al.* 2012). Thus, while the specific site of cleavage within the peptidoglycan and the structure of Tae1 are known explicitly, the interactions that determine the cleavage specificity of Tae1 remain unknown.

This prompted us to ask whether solution-state Nuclear Magnetic Resonance spectroscopy (NMR) might reveal the molecular features of Tae1 that lead to the observed cleavage specificity.




Figure 11: Tae1 crystal structure a fragment of PG modeled in the binding cleft in one possible conformation within the active site. Catalytic residues Cys30 and His91 labeled yellow and red respectively.

For proteins the relationship between structure and function is well-established thanks to the molecular-level insights provided by X-ray crystallography and NMR (Ziarek *et al.* 2011). X-ray crystallography is the gold standard for protein structure determination, however it has multiple limitations. Its greatest limitation is the necessity of crystallization of the protein and substrate (Williamson *et al.* 2013). To

analyze the structure of proteins in solution NMR is the superior technique. NMR is limited in its application by the size of the analyte. At $\sim 17\text{kDa}$, Tae1 it is well within the range of molecular weights for which NMR is tractable (Cavanagh *et al.* 2010).

NMR relies on the nuclear spin of atoms with odd mass numbers in that such nuclei have magnetic moments. Within a strong external magnetic field (B_0) the nuclear magnetic moments will align with that of B_0 . Nuclear magnetic moments exhibit Larmor precession around the axis of the external magnetic field as shown in Figure 12. The greater the strength of B_0 the higher the frequency of the precession.





Figure 12: Larmor precession of nuclear spins in an external magnetic field.

The Larmor precession of the individual nuclear spins in the protein cannot be observed directly (Cavanagh *et al.* 2010). The individual precessing magnetic moments of the various nuclei sum together to form a single vector in the direction of B_0 (Cavanagh *et al.* 2010). To observe the nuclear magnetization we must force the

magnetization perpendicular to B_0 . This is achieved by applying a radio pulse with the same frequency as the Larmor precession (Cavanagh *et al.* 2010). After the pulse, the nuclear magnetization vector will then be perpendicular to the external magnetic field and the angular rate of rotation will induce an electric current which can be measured in a receiver coil surrounding the sample (Hore *et al.* 2000). Over time the perpendicular magnetization will decrease as the magnetization relaxes to align with B_0 (Cavanagh *et al.* 2010). Thus, the amplitude at the receiver coil will decrease over time and provide a measurement known as the free induction decay, or FID (Figure 13; Hore *et al.* 2000).

By applying a Fourier transform (FT) to the FID one is able to deconvolute the FID into a dataset that resolves the resonance frequencies for individual nuclei (Cavanagh *et al.* 2010). The NMR active nuclei of the molecule exist in different chemical environments and thus can be distinguished from one another by their characteristic chemical shifts (Cavanagh *et al.* 2010). In the work described herein, we are exploiting the fact that changes in the local chemical environment, such as protein-substrate binding, are associated with changes in the local magnetic environment of a given nucleus. This is manifested as a change in the chemical shift for that nucleus, and is the key piece of information needed to map which atoms in the protein are likely involved in substrate binding.



NMR Signal :
 Alternating magnetic field from the sample induces electric current in the coils

Figure 13: NMR data workflow. Image generated by Dr. Serge Smirnov at Western Washington University, Department of Biochemistry.

Figure 14 shows a one-dimensional (1D) spectrum of ^1H resonances for the 76-residue peptide ubiquitin. As is evident from Figure 14, there is substantial overlap in the resonances of the 629 ^1H nuclei in ubiquitin in a 1D NMR spectrum, making the resolution of individual resonances impossible. To achieve resolution of these signals so-called multi-dimensional experiments are necessary.




Figure 14: 1D ^1H -NMR spectrum of the small protein ubiquitin. The spectrum was acquired on a 500 MHz instrument. The ranges of chemical shifts for aliphatic, aromatic, and amide protons are indicated. Mathews et al. "Biochemistry 4th edition", pg 225.

To perform a multi-dimensional experiment it is necessary to enrich the protein in the NMR-active nuclei ^{15}N and/or ^{13}C , both of which are present in low natural abundance. Figure 15 shows the amide ^1H resonances for ubiquitin resolved in a two dimensional NMR experiment (^{15}N -HSQC) that records individual ^1H spectra as a function of ^{15}N chemical shift. The individual backbone amide ^1H resonances can be completely resolved using this approach. For larger proteins there may be overlap of resonances in the ^{15}N HSQC. Individual resonances can then be resolved by collecting a 3D dataset which includes a series of ^{15}N HSQC spectra recorded as a function of ^{13}C

chemical shift. Such 3D datasets are also needed to assign the individual resonances in the HSQC spectrum to particular amino acids in the protein sequence.




Figure 15: Display of 2D Protein NMR experiment. Due to the complexity of proteins it is necessary to utilize multi-dimensional experiments. A proton spectrum is collected at each nitrogen shift. If compiled together into a single proton spectrum the amount of data is overly convoluted. By working with the data in two dimensions it is possible to resolve the peaks and gain valuable information for each residue. Most commonly this is imaged from the top down as a topographic map as shown in Figure 16. Mathews et al. "Biochemistry 4th edition", pg 226 (Figure generated by S. Smirnov).




Figure 16: 2D NMR top down “topographical” map view of a standard NHSQC where each spot is a peak from the two dimensional spectrum. Mathews *et al.* “Biochemistry 4th edition”, pg 226 (Figure generated by S. Smirnov).

The changes in the chemical environment of the protein upon binding of a specific substrate lead to changes in the positions and intensities of peaks in the HSQC spectrum (Cavanagh *et al.* 2010). Depending on the relative rates of ligand binding and NMR data acquisition, the changes to the peaks in the HSQC spectrum will be observed in different ways. If the association of the protein and its ligand occurs faster than the NMR acquisition time, a shift in the peak is observed (Hole *et al.* 2000). If instead the rates of ligand binding and release occur on the same timescale as the NMR acquisition time, peak broadening will be observed (Hole *et al.* 2000). Finally, if the ligand binding/release is slower than the NMR acquisition time, a peak doubling will occur

(Hole *et al.* 2000). The changes in peak position and/or intensity can be used to map the sites on the protein that are most affected by ligand binding.

For an NMR investigation of the interaction between an enzyme which cleaves its substrate, such as Tae1 and peptidoglycan, it is necessary to inhibit the activity of the enzyme to allow for NMR data collection on a homogenous sample. (Cavanagh *et al.* 2010). If Tae1 maintains its amidase activity then the interaction between Tae1 and PG will be over too quickly for observation by NMR. To get around this problem a point mutation was made which inactivates the enzyme by replacing the essential cysteine nucleophile with alanine. This mutation does not otherwise effect the structure of the protein (Vivian *et al.* 2003). Unfortunately, this mutation did not facilitate the co-crystallization of Tae1 with PG fragments. Nevertheless, we hope to use NMR to determine which residues in Tae1 are responsible for PG binding.

Methods

Tae1 containing a C-terminal hexahistidine tag was expressed and purified as described (Chou *et al.* 2012). Briefly, soluble protein was isolated from clarified lysate by metal affinity chromatography followed by size-exclusion chromatography

PG fragments were isolated from *B. subtilis*. Both liquid media and plate growth were attempted to determine best method for bacterial production. For plate growth *B. subtilis* seed stock was inoculated on rich plate media and held in a constant temperature incubator overnight. Subsequently the bacterial colonies were scraped off of the plates with a glass stir rod and ice cold saline and collected in a flask. Liquid media growth was performed in LB medium inoculated with *B. subtilis* seed stock and held overnight in a constant temperature shaker.

In both cases once the growth was complete bacterial cells were harvested by high speed centrifugation with two washes of cold sodium chloride solution, one of water, and three final washes with acetone. Subsequently the washed cell pellet is dried at 37°C. The dried bacterial cells are then suspended in ice-cold water and transferred to 2mL “bead beater” tubes containing roughly five 0.10-0.15mm glass beads. These samples are then treated in a bead beater for four two-minute intervals for a total of 8 minutes with cooling on ice for 6 minutes in between rounds. The mixture of broken cells and glass beads is filtered. The cell walls are then separated from the supernatant by ten minutes of centrifugation at 1500 x g and 4 °C. The pelleted cell walls were washed three times with water, and then resuspended in 200 mL of pH 7.6 phosphate buffer. To this suspension RNase A was added to a final concentration of 100

$\mu\text{g/ml}$, DNase to a final concentration of $50 \mu\text{g/mL}$, along with 0.5mL toluene. This mixture was then incubated at 37°C for 18hr at which point sterile trypsin was added to a final concentration of $200 \mu\text{g/ml}$ and incubated for a further 18 hours at 37°C . After the final incubation period the cell walls were pelleted by high speed centrifugation as described above, washed three times with water, and finally lyophilized.

NMR data was collected on a 500 Mhz Bruker instrument in the lab of Rachel Klevit. Data was processed with NMRpipe using scripts provided by Dr. Peter Brzovic.

NMR assignment was performed utilizing the “NMRviewJ” software suite from One Moon Scientific. Assignments of backbone amides in the NHSQC spectrum, were carried out by analysis of data from HCONH, HNCACB, HNCB, and HCCONH experiments. For the side chain assignments, HCCH COSY and HCCH TOCSY peaks were individually peak-picked and assigned by hand. Multiple attempts were made to achieve the best assignment possible for the CHSQC using combinations of the ppm assignments from the previously assigned side chain experiments. Side chain assignments were checked against average values from the Biological Magnetic Resonance Bank (BMRB; <http://www.bmrwisc.edu/>). This initial assignment was checked further utilizing the NMRviewJ “atom assign” tool. Each assignment was also checked against the X-ray crystal structure to make sure that the proposed assignments fell within established ranges for a given residue in the context of the predicted secondary structure.

A typical assignment workflow requires working through a single sidechain at a time, cross-referencing the paired experiments (i.e., HCCH TOCSY and HCCH COSY) to make sure that the assignments match. Due to the high number of shared resonances

between similar amino acid side chains it was helpful to resolve these shared resonances by comparing residue assignments with the location found in the X-ray crystal structure and against BMRB standards. A typical assignment for a single side chain can take several hours to complete. For the NMR titration analysis, the changes in peak intensity for each resonance are graphically compared, normally after their overall change has been normalized to one, as observed in Appendices 4 and 5.

Results

The initial characterization of Tae1 assigned 89.2% of the backbone amides and 87.4% of side chains, Figures 17-20. Factors that limit the completion of assignments include the absence of peaks for prolines, and the inability to differentiate between reciprocal/mirror-imaged systems (such as the two delta carbons and 6 delta hydrogens found in Leucine). In these cases, the peak in the spectrum was labeled with a shared assignment. Of the non-assigned residues displayed in grey in figures 17 and 18, there are six proline residues, furthermore the unassigned active site proximal extension is composed of Thr88 and Tyr89, and the unassigned residue to the far right of the catalytic His91 is Arg132. As the backbone assignments are necessary for sidechain assignment, the percentage of residues with backbone assignments represents the upper limit of what can be achieved for sidechain assignments. Therefore, 87.4% side chain assignments represents a nearly full coverage of all assignable sidechain residues in NMR experiments. These assignments set the stage for investigating the binding of Tae1 with Hcp1 and peptidoglycan.




Figure 17: Pymol image of Tae1 with assigned backbone residues colored in green, and unassigned residues colored in grey. Catalytic residues Cys 30 and His 91 colored red and yellow respectively




Figure 18: Pymol image of the backside of Tae1 with assigned backbone residues colored in green, and unassigned residues colored in grey.




Figure 19: Pymol image of Tae1 with assigned side chain residues colored in green, and unassigned residues colored in grey. Catalytic residues Cys 30 and His 91 colored red and yellow respectively




Figure 20: Pymol image of the backside of Tae1 with assigned side chain residues colored in green, and unassigned residues colored in grey

After the assignment of the backbone amides for Tae1 an NMR titration was performed by incubating ^{15}N -labeled Tae1 with increasing concentrations of Hcp1 (Figure 21) and the non-binding Hcp1 mutant S115Q, with the expectation that the addition of increasing wild type Hcp1 would affect certain Tae1 resonances, whereas the S115Q mutant would not show any effect (Silverman *et al.* 2013). As can be observed in figure 22 and 23 there were little to no observable changes in the spectra through the series of the titrations. Shown in Appendix 4 and 5 are the graphical analyses of the titrations which show that the only quantitative change is a decrease in overall spectral intensity as a function of increasing concentrations of Hcp1.




Figure 21: NHSQC overlay of *Tae1* titration with *Hcp1*. The red box displays the region of the spectrum utilized in Figures 22 and 23




Figure 22: Representative panels from NHSQC titration of *Tae1* with increasing concentrations of *Hcp1*




Figure 23: Representative panels from NHSQC titration of Tae1 with increasing concentration of Hcp1 mutant S115Q.

To explore binding of Tae1 with its putative substrate Tae1 titrations with a mucopeptide containing the L-Ala-D-Glu-mDAP crosslink within a series of 9 residues with a single GlcNac moiety bound to the mucopeptide known as the “tetra-tetra” fragment of PG (see figure 24) were also performed, but yielded no evidence for specific binding.




Figure 24: NHSQC overlay of *Tae1* (black) and *Tae1* incubated with tetra-tetra fragment (displayed in upper left corner of the spectrum) of PG (teal). Spectra collected by Drs Seemay Chou and Jonathan Pruneda at University of Washington.




Figure 25: CHSQC of *Tae1* with the spectral region displayed in figure 26 highlighted in red.

To generate side chain assignments, the CHSQC spectrum of Tae1 was assigned using the NHSQC assignments as well as C atom resonances observed in the following experiments: CCONH TOCSY, HCCONH TOCSY, HCCH COSY, and HCCH TOCSY. Owing to the vast amount of information on the CHSQC spectrum it was extremely difficult to resolve assignments for individual residues, however 70% of the peaks could be assigned, as shown in Appendix 2. This provided coverage of at least a portion of the protons for every single side chain residue that could be assigned (e.g., Pro residues are not assignable). While not every proton for each side-chain could be assigned, the spectral coverage of Tae1 in side chain displaying experiments is very robust.

Upon incubation of triple-labeled Tae1 with intact sacculi we observed several peaks disappearing from the spectrum. To investigate the role of the glycan strand in the binding, Dr. Chou subsequently incubated this sample with lysozyme. Interestingly when a CHSQC spectrum was collected, all of the peaks that disappeared returned following the lysozyme treatment (Figure 26).




Figure 26: CHSQC spectra of Tae1 (black), Tae1 incubated with whole sacculi (red), and Tae1 incubated with whole sacculi then with lysozyme (blue)

Discussion

The experimental approach that we took for this project was the application of NMR to investigate the binding of the toxic amidase effector Tae1 with potential regulatory factor Hcp1 and Tae1's PG substrate. Our objective was to identify the residues of Tae1 which are responsible for determining the apparent specificity of PG cleavage by Tae1.

Standard NHSQC-based NMR titration experiments of PG fragments with Tae1 have not yet yielded any evidence that explains the apparent cleavage specificity of the amidase. Nor does Tae1 appear to bind Hcp1 with any specificity. Hcp1 had been shown to bind a different effector based on EM analysis, and given the role of Hcp1 in the

assembly of the secretion apparatus, we hypothesized that Tae1 would also associate with Hcp1 (Silverman *et al.* 2013).

The only evidence for binding in NHSQC-based experiments was observed at low pH (pH 5.0) for a side chain amide (Figure 24). We therefore turned to CHSQC experiments to probe the details of Tae1 side chain interactions with putative substrates.

CHSQC titrations show that the addition of intact sacculi results in the disappearance of several peaks; however, these peaks also showed a small signal to noise ratio prior to addition of the sacculi. Thus, differential effects on peak intensity of chemical shift were impossible to discern in this experiment. Interestingly, these peaks returned upon addition of lysozyme to this sample.

This result suggests that the glycan strand must be intact for Tae1 to bind. If this is true, it would explain the lack of specific interactions in the NHSQC titration experiments using PG fragments (in which the glycan portion was absent). Lysozyme cleaves PG between the GlcNac (NAG) and MurNac (NAM), but leaves the peptide region intact. We theorize that the binding affinity of Tae1 for PG is greater when the glycan strand is intact; however, it is unclear how (if at all) the glycan affects Tae1 cleavage specificity for the peptide portion of PG.

Intact sacculi are too large to allow us to probe specific interactions with Tae1 via NMR. PG fragments of defined size that include intact NAG-NAM bonds would be more amenable to NMR analysis; however, such fragments are not produced by the methods commonly used to generate PG fragments from sacculi.

Chemical synthesis has been used to generate defined PG fragments with intact glycan bonds. This method was utilized by Mellroth *et al.* however, this necessitated a thirty step synthesis which would be cost prohibitive for NMR-based investigations (Mellroth *et al.* 2014).

To generate appropriately sized PG fragments we have attempted fragmentation of purified PG sacculi through a combination of sonication and limited digestion with lysozyme. While this has not yet yielded the desired fragments, a future goal is to optimize this process to generate fragments of appropriate size and composition for NMR experiments.




Figure 27: Cartoon representation of minimal binding fragment generation/isolation experiment theory. By utilization of stepwise addition of Lysozyme or sonication the goal will be to isolate fragments of a size small enough that they don't completely obscure the signal in NMR experiments as seen with intact sacculi, but with the necessary size and complexity that binding can occur and be observed.

In collaboration with the Vollmer lab, sacculi which have been treated with a muramidase (e.g., lysozyme) will be subsequently treated with catalytically active, wild-type, Tae1. As displayed in appendix 6, based on the results shown in Figure 10, we expect that this order of addition, muramidase then Tae1, will lead to reduced cleavage of the peptide portion of the PG. If significant cleavage of the PG peptides is observed in this experiment we would then need to examine whether the active site Cys to Ala mutation has impaired Tae1 binding to PG fragments compared to wild-type Tae1. The data in Figure 26 suggest that the presence of glycan strands in the PG fragments is required for Tae1 binding. A similar observation was reported by Mellroth *et al.* for the pneumococcal autolysin LytA (Mellroth *et al.* 2014). They found that having a GlycNac on both sides of the muropeptide was necessary for cleavage of PG by LytA. Furthermore, the cleavage of this PG fragment was reduced compared to cleavage of PG fragments with longer glycan strands. Upon further study, as reported in a recently released paper *in press*, Mellroth *et al.* successfully co-crystallized LytA with a large PG fragment (diGM5P) spanning four GlcNac/MurNac alternating residues linked to an L-Ala-D-Glu-L-Lys-D-Ala-D-Ala pentapeptide (Sandalova *et al.* 2016). This result supports our hypothesis of the necessity of a larger PG fragment for experimentally observable binding.

Solid state NMR (ssNMR) is a powerful technique which has been utilized in the study of PG and provided the first atomic model of an enzyme in complex with an intact bacterial PG sacculus (Schanda *et al.* 2015). Because of the size and dynamic nature of PG it is challenging to analyze large PG fragments via solution state NMR or X-ray

crystallography. Solid state NMR may be a useful method for future investigations of Tae1 interactions with larger PG fragments, however, the low sensitivity of ssNMR is of concern; while experiments showed effects within the PG from the binding of an L-D-transpeptidase from *B. subtilis* bound to its PG substrate the technique lacked the sensitivity required to determine atomic detail of the interaction of the protein itself (Schanda *et al.* 2015).

The challenges associated with the production/isolation of a suitable PG substrate of Tae1 have limited our ability to determine the atomic-level details of Tae1 binding to PG. However, our assignments of both the backbone and sidechain residues in Tae1 will allow for such determination as soon as a minimal binding fragment of PG can be isolated and characterized. Future work will be necessarily focused on development of such a minimal binding PG fragment.

Works Cited

1. Brown S., Santamaria J.P., Walker S. Wall teichoic acids of gram-positive bacteria. *Annu Rev Microbiol.* 2013; 67:313-36.
2. Cavanagh J., Fairbrother W.J., Palmer A.G., Skelton N.J., Rance M. Protein NMR Spectroscopy, Principles and Practice. Academic Press; 2010.
3. Chou S., Bui N.K., Russell A.B., Lexa K.W., Gardiner T.E., LeRoux M., Vollmer W., Mougous J.D. Structure of a peptidoglycan amidase effector targeted to Gram-negative bacteria by the type VI secretion system. *Cell Rep.* 2012; 1(6):656-64.
4. Desmarais, S.M., Cava, F., de Pedro, M.A., Huang, K.C. Isolation and Preparation of Bacterial Cell Walls for Compositional Analysis by Ultra Performance Liquid Chromatography. *J. Vis. Exp.* 2014; 83: e51183.
5. Gan L., Chen S., Jensen G.J. Molecular organization of Gram-negative peptidoglycan. *Proc Natl Acad Sci USA.* 2008; 105(48):18953-7.
6. Hore P.J., Jones J.J., Wimperis S. NMR, The Toolkit. Oxford University Press; 2000.
7. Kern T., Giffard M., Hediger S., Amoroso A., Guistini C., Khai Bui N., Joris B., Bougault C., Vollmer W., Simorre J.P. Dynamics characterization of fully hydrated bacterial cell walls by solid-state NMR: evidence for cooperative binding of metal ions. *J. Am. Chem. Soc.* 2010; 132(31):10911-9.

8. Kleckner I.R., Foster M.P. An introduction to NMR-based approaches for measuring protein dynamics. *Biochim Biophys Acta*. 2011; 1814(8):942-68.
9. Kühner D., Stahl M., Demircioglu D.D., Bertsche U. From cells to muropeptide structures in 24 h: peptidoglycan mapping by UPLC-MS. *Sci Rep*. 2014; 4:7494.
10. Lehotzky R.E., Partch C.L., Mukherjee S., Cash H.L., Goldman W.E., Gardner K.H., Hooper L.V. Molecular basis for peptidoglycan recognition by a bactericidal lectin. *Proc. Natl. Acad. Sci. USA*. 2010; 107(17):7722-7.
11. Leroux M., De leon J.A., Kuwada N.J., Russel A.B., Pinto-Santini D., Hood R.D., Agnello D.M., Robertson S.M., Wiggins P.A., Mougous J.D. Quantitative single-cell characterization of bacterial interactions reveals type VI secretion is a double-edged sword. *Proc. Natl. Acad. Sci. USA*. 2012; 109(48):19804-9.
12. Mellroth P., Sandalova T., Kikhney A., Vilaplana F., Heseck D., Lee M., Mobashery S., Normark S., Svergun D., Henriques-Normark B., Achour A. Structural and functional insights into peptidoglycan access for the lytic amidase LytA of *Streptococcus pneumoniae*. *mBio*. 2014; 5(1):1120-13.
13. Mathews C.K., Van Holde K.E., Appling D.R., Anthony-Cahill S.J. *Biochemistry*. Toronto: Pearson, 2013. Print.
14. Otero L.H., Rojas-Altuve A., Llarrull L.I., Carrasco-López C., Kumarasiri M., Lastochkin E., Fishovitz J., Dawley M., Heseck D., Lee M., Johnson J.W., Fisher J.F., Chang M., Mobashery S., Hermoso J.A. How allosteric control of *Staphylococcus*

- aureus penicillin binding protein 2a enables methicillin resistance and physiological function. *Proc. Natl. Acad. Sci. USA*. 2013; 110(42):16808-13.
15. Romaniuk J.A., Cegelski L. Bacterial cell wall composition and the influence of antibiotics by cell-wall and whole-cell NMR. *Phil. Trans. R. Soc. B* 2015; 370(1679). <http://dx.doi.org/10.1098/rstb.2015.0024>
16. Russell A.B., Hood R.D., Bui N.K., Leroux M., Vollmer W., Mougous J.D. Type VI secretion delivers bacteriolytic effectors to target cells. *Nature*. 2011; 475(7356):343-7.
17. Russell A.B., Singh P., Brittnacher M., Bui N.K., Hood R.D., Carl M.A., Agnello D.M., Schwarz S., Goodlett D.R., Vollmer W., Mougous J.D. A widespread bacterial type VI secretion effector superfamily identified using a heuristic approach. *Cell Host Microbe*. 2012; 11(5):538-49.
18. Sandalova T., Lee M., Henriques-Normark B., Heseck D., Mobashery S., Mellroth P., Achour A. The Crystal Structure of the minor pneumococcal autolysin LytA in complex with a large peptidoglycan fragment reveals the pivotal role of glycans for lytic activity. Accepted article, doi: 10.002/mmi.13435.
19. Schanda P., Triboulet S., Laguri C., Bougault C.M., Ayala I., Callon M., Arthur M., Simore J.P. Atomic model of a cell-wall cross-linking enzyme in complex with an intact bacterial peptidoglycan. *J Am Chem Soc*. 2014; 136(51):17852-60.
20. Shang G., Liu X., Lu D., Zhang J., Li N., Zhu C., Lui S., Yu Q., Zhang H., Hu J., Cang H., Xu S., Gu L. Structural insight into how *Pseudomonas aeruginosa*

- peptidoglycan hydrolase Tse1 and its immunity protein Tsi1 function. *Biochem. J.* 2012; 448(2):201-11.
21. Silhavy T.J., Kahne D., Walker S. The bacterial cell envelope. *Cold Spring Harb. Perspect. Biol.* 2010; 2(5):a000414.
22. Silverman J.M., Agnello D.M., Zheng H., Andrews B.T., Li M., Catalano C.E., Gonen T., Mougous J.D. Haemolysin coregulated protein is an exported receptor and chaperone of type VI secretion substrates. *Mol. Cell.* 2013; 51(5):584-93.
23. Silverman J.M., Brunet Y.R., Cascales E., Mougous J.D. Structure and regulation of the type VI secretion system. *Annu. Rev. Microbiol.* 2012; 66:453-72.
24. Taneja N., Kaur H. Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria. *Microbiology Insights* 2016; 9: 9–19.
25. Typas A., Banzhaf M., Gross C.A., Vollmer W. From the regulation of peptidoglycan synthesis to bacterial growth and morphology. *Nat Rev. Microbiol.* 2012; 10(2):123-36.
26. Vivian J.P., Hastings A.F., Duggin I.G., Wake R.G., Wilce M.C.J., Wilce J.A. The impact of single cysteine residue mutations on the replication terminator protein. *Bioch. Biophys. Res. Comm.* 2003; 310(4): 1096-1103.
27. Williamson M.P. Using chemical shift perturbation to characterize ligand binding. *Prog. Nucl. Magn. Reson. Spectrosc.* 2013; 73:1-16.

28. Ziarek J.J., Peterson F.C., Lytle B.L., Volkman B.F. Binding site identification and structure determination of protein-ligand complexes by NMR a semi-automated approach. *Meth. Enzymol.* 2014; 493: 241-75.

Table of Appendices

1. Appendix 1: Residue assignments for Tae1 in NHSQC, HCACB, CCONH TOCSY, HCCONH TOCSY
2. Appendix 2: Residue assignments for Tae1 in HCCH COSY, and HCCH TOCSY
3. Appendix 3: NHSQC Spectrum with assignments displayed. Assigned backbone amides are displayed by a black box, amides or amines in side chains are displayed in red.
4. Appendix 4: CHSQC Spectrum with assignments displayed. Residues with full assignment are displayed by a black box, those that do not have assignment are displayed in red.
5. Appendix 5: Graphical comparison of Tae1/Hcp1 titration. Change in intensity
6. Appendix 6: Graphical comparison of Tae1/Hcp1 S115Q titration
7. Appendix 7: Experimental design for confirmation of Tae1 minimal binding fragment specificity

Appendix 1: Residue assignments for Tae1 in NHSQC, HCACB, CCONH TOCSY, and HCCONH TOCSY Experiments

| Protein | | NHSQC | | HCACB | | CCONH | | | | | HCCONH | | | | | | | | |
|---------|-----|-------|---------|--------|--------|--------|--------|--------|--------|--------|---------|---------|---------|---------|---------|---------|---------|-----|---------|
| Res | Num | H | N | CA | CB | CA | CB | CG | CG2 | CD | HA | HA2 | HB | HB2 | HG | HG2 | HD | HD2 | HE |
| MET | 1 | -- | -- | -- | -- | | | | | | | | | | | | | | |
| ASP | 2 | -- | -- | 54.991 | 41.744 | 54.474 | 41.504 | | | | 4.69 | | 2.72 | 2.56 | | | | | |
| SER | 3 | 8.477 | 115.399 | 58.452 | 64.495 | 58.107 | 64.797 | | | | 4.59875 | | 3.95954 | | | | | | |
| LEU | 4 | 8.858 | 126.106 | 55.583 | 42.069 | 55.448 | 41.801 | | | | 4.49136 | | 2.88679 | | 1.5647 | | 0.84878 | | |
| ASP | 5 | 8.15 | 114.38 | 54.174 | 40.562 | 54.110 | 40.286 | | | | 4.6184 | | 3.00162 | | | | | | |
| GLN | 6 | 8.023 | 122.191 | 60.231 | 28.186 | 59.968 | 28.021 | 33.984 | | | 3.82711 | | 2.10604 | | 2.40331 | | | | |
| CYS | 7 | 8.459 | 116.846 | 61.559 | 35.703 | 61.659 | 35.498 | | | | 4.67705 | | 3.45002 | 3.0081 | | | | | |
| ILE | 8 | 7.464 | 126.476 | 64.75 | 39.048 | 64.744 | 38.831 | 29.150 | 18.082 | 13.488 | 5.37467 | | 3.71812 | | 2.12487 | 1.72471 | 0.92207 | | |
| VAL | 9 | 8.15 | 122.258 | 68.065 | 32.021 | 67.806 | 31.839 | 23.123 | 21.776 | | 3.11208 | | 2.03669 | | 1.0394 | | | | |
| ASN | 10 | 8.736 | 117.342 | 56.382 | 37.813 | 55.880 | 37.527 | | | | 4.26073 | | 2.72322 | | | | | | |
| ALA | 11 | 7.162 | 121.985 | 55.287 | 18.806 | 54.722 | 18.597 | | | | 4.24875 | | 1.45162 | | | | | | |
| CYS | 12 | 8.211 | 120.877 | 64.055 | 25.658 | 63.741 | 25.423 | | | | 3.68836 | | 2.30153 | 1.11445 | | | | | |
| LYS | 13 | 7.975 | 119.047 | 60.233 | 32.683 | 59.946 | 32.426 | 25.971 | | | 3.7635 | | 1.80569 | | 1.32812 | | 1.53205 | | 3.04538 |
| ASN | 14 | 8.207 | 116.238 | 55.278 | 38.816 | 55.556 | 38.489 | | | | 4.53071 | | 2.9785 | 2.76335 | | | | | |
| SER | 15 | 7.878 | 113.896 | 61.468 | 64.107 | 61.196 | | | | | 4.1722 | | 3.74287 | 3.52298 | | | | | |
| TRP | 16 | 8.017 | 124.298 | 61.414 | 31.464 | 61.262 | 31.240 | | | | 4.45729 | | 3.86148 | 3.50156 | | | | | |
| ASP | 17 | 7.918 | 111.341 | 54.733 | 42.171 | | | | | | 4.83736 | | 2.9922 | 2.61317 | | | | | |
| LYS | 18 | 7.125 | 119.195 | 56.347 | 35.608 | 56.347 | | | | | | | | | | | | | |
| SER | 19 | -- | -- | 56.648 | 64.416 | 56.347 | | | | | 4.54131 | | 3.61572 | | | | | | |
| TYR | 20 | 8.987 | 127.628 | 62.765 | 39.855 | | 39.625 | | | | 3.79315 | | 2.40576 | | | | | | |
| LEU | 21 | 8.07 | 118.561 | 52.985 | 42.906 | 52.813 | 42.633 | 27.008 | | | 4.28742 | | 1.55654 | | 1.43385 | | 0.89242 | | |
| ALA | 22 | 8.212 | 126.765 | 54.476 | 19.694 | | 17.753 | | | | 3.89807 | | 1.27652 | | | | | | |
| GLY | 23 | 8.599 | 111.624 | 45.809 | -- | 45.514 | | | | | 4.19563 | 3.69123 | | | | | | | |
| THR | 24 | 8.33 | 118.237 | 59.67 | 71.438 | | | | | | | | | | | | | | |
| PRO | 25 | -- | 123.119 | 63.261 | 32.963 | 63.106 | 32.821 | 27.855 | | | 4.46652 | | 2.27885 | 2.04241 | 1.80369 | | 3.80493 | | |
| ASN | 26 | 9.156 | 123.154 | 55.662 | 37.701 | | | | | | 4.44677 | | 3.35868 | 2.58078 | | | | | |
| LYS | 27 | 7.548 | 116.213 | 58.558 | 30.28 | | | | | | 4.73406 | | 1.46687 | | 0.94232 | 0.67041 | 0.20659 | | 2.8602 |
| ASP | 28 | 7.289 | 118.843 | 53.575 | 42.746 | 53.526 | 42.438 | | | | 4.90088 | | 2.9686 | | | | | | |
| ASN | 29 | 7.327 | 116.395 | 52.808 | 40.542 | 52.659 | 40.267 | | | | 4.70873 | | 2.82526 | 2.56351 | | | | | |
| ALA | 30 | 9.119 | 127.538 | 56.984 | 21.329 | | 21.085 | | | | 4.12611 | | 1.91277 | | | | | | |
| SER | 31 | 8.582 | 111.651 | 61.111 | 62.67 | 60.799 | | | | | 4.13514 | | 3.70235 | | | | | | |
| GLY | 32 | 7.248 | 111.14 | 48.169 | -- | | | | | | 4.19563 | | | | | | | | |
| PHE | 33 | 8.342 | 118.522 | 63.208 | 38.556 | 63.140 | 38.289 | | | | 3.98943 | | 3.3406 | 3.08377 | | | | | |
| VAL | 34 | 7.22 | 116.465 | 67.556 | 31.668 | 67.120 | | | | | 3.06404 | | 1.86513 | | 1.12695 | | | | |
| GLN | 35 | 8.363 | 118.109 | -- | -- | | | | | | | | | | | | | | |
| SER | 36 | 8.42 | 118.362 | 64.025 | 62.569 | 64.025 | | | | | | | 3.85192 | | | | | | |
| VAL | 37 | 7.613 | 125.241 | 67.708 | 32.121 | 67.346 | 31.780 | | | | 3.05024 | | 1.81217 | | 0.69161 | 0.29578 | | | |
| ALA | 38 | 8.284 | 119.717 | 55.854 | 18.53 | 55.354 | | | | | 3.65339 | | 1.45397 | | | | | | |

| | | | | | | | | | | | | | | | | | |
|-----|----|-------|---------|--------|--------|--------|--------|--------|--------|---------|---------|---------|---------|---------|--|---------|---------|
| ALA | 39 | 8.009 | 119.157 | -- | 18.114 | | 17.852 | | | 4.13455 | | 1.5553 | | | | | |
| GLU | 40 | 7.852 | 120.307 | 59.711 | 29.289 | 59.555 | 29.449 | 36.325 | | 3.96569 | | 2.06063 | | 2.22128 | | | |
| LEU | 41 | 7.436 | 115.601 | 55.071 | 43.526 | 54.723 | 43.171 | 28.608 | | 4.21846 | | 1.65782 | | 1.66927 | | 0.78635 | |
| GLY | 42 | 7.912 | 110.459 | 46.589 | -- | | | | | 3.99067 | 3.7851 | | | | | | |
| VAL | 43 | 8.154 | 124.097 | 59.7 | 34.29 | | | | | | | | | | | | |
| PRO | 44 | -- | -- | 63.136 | 31.914 | 62.937 | 31.800 | 27.559 | | 4.27804 | | 2.20319 | | 1.95389 | | 3.49628 | |
| MET | 45 | 7.96 | 122.777 | 51.1 | 35.112 | | | | | | | | | | | | |
| PRO | 46 | -- | -- | 63.181 | 32.639 | 62.984 | 32.639 | 27.197 | | 4.33287 | | 2.32139 | | 1.61525 | | | |
| ARG | 47 | 8.038 | 120.031 | 55.893 | 32.283 | 55.668 | 31.990 | 27.429 | 43.484 | 4.23827 | | 1.70585 | | 1.70585 | | 3.2054 | |
| GLY | 48 | 7.978 | 106.298 | 44.357 | -- | 44.256 | | | | 4.41018 | 3.65941 | | | | | | |
| ASN | 49 | 7.848 | 115.2 | 51.883 | 38.12 | | | | | 4.30089 | | 3.54008 | | | | | |
| ALA | 50 | 8.398 | 119.176 | 56.94 | 18.544 | 56.940 | 18.293 | | | | | | | | | | |
| ASN | 51 | 8.204 | 116.394 | 56.1 | 37.484 | 56.002 | 37.291 | | | 4.41721 | | 2.81998 | | | | | |
| ALA | 52 | 7.862 | 122.031 | 55.028 | 18.479 | 55.214 | 18.272 | | | 4.12574 | | 1.5155 | | | | | |
| MET | 53 | 8.973 | 120.368 | 60.215 | 33.527 | 59.903 | | | | 3.43528 | | 1.96741 | | 2.23854 | | | 1.69152 |
| VAL | 54 | 8.152 | 119.353 | 68.115 | 31.042 | 67.893 | 30.888 | | | 3.0813 | | 2.02515 | | 0.96654 | | | |
| ASP | 55 | 7.668 | 117.935 | 58.173 | 40.475 | 58.088 | 40.194 | | | 4.31126 | | 2.70982 | 2.55045 | | | | |
| GLY | 56 | 7.886 | 106.567 | 47.359 | -- | 47.069 | | | | 3.87926 | 3.40324 | | | | | | |
| LEU | 57 | 8.586 | 127.345 | 58.195 | 39.162 | | | | | | | | | | | | |
| GLU | 58 | -- | -- | 59.312 | 29.272 | 59.069 | 29.272 | 35.395 | | 4.05312 | | 2.1219 | | 2.34787 | | | |
| GLN | 59 | 7.176 | 113.464 | 57.518 | 29.847 | 57.369 | | 33.927 | | 4.30103 | | 2.19481 | | 2.52359 | | | |
| SER | 60 | 7.695 | 110.005 | 60.54 | 67.061 | 60.203 | | | | 4.97129 | | 4.02243 | | | | | |
| TRP | 61 | 9.435 | 126.188 | 57.291 | 30.829 | | | | | | | | | | | | |
| THR | 62 | 8.389 | 118.896 | 64.289 | 70.212 | 64.093 | | 21.761 | | 4.25978 | | 4.04431 | | 1.12968 | | | |
| LYS | 63 | 8.683 | 127.093 | 55.934 | 34.252 | 55.550 | 33.948 | | | 5.12804 | | 1.78238 | | 1.38951 | | 1.38951 | 2.9802 |
| LEU | 64 | 8.751 | 124.258 | 53.362 | 44.021 | 53.203 | 43.723 | | | 4.58268 | | 1.55564 | | | | 0.68609 | |
| ALA | 65 | 8.776 | 120.673 | 54.026 | 20.38 | | 20.119 | | | 4.34552 | | 1.45702 | | | | | |
| SER | 66 | 7.138 | 106.868 | 56.858 | 66.729 | | | | | 4.83417 | | 4.0317 | | | | | |
| GLY | 67 | 8.836 | 110.291 | 46.115 | -- | | | | | 3.56359 | 2.70438 | | | | | | |
| ALA | 68 | 8.118 | 124.097 | 55.337 | 18.211 | | 17.996 | | | 3.9992 | | 1.29481 | | | | | |
| GLU | 69 | 7.764 | 119.592 | 59.336 | 30.463 | 59.145 | 30.651 | 37.406 | | 3.91654 | | 1.99624 | | 2.23641 | | | |
| ALA | 70 | 7.498 | 121.645 | 55.515 | 19.588 | | 19.315 | | | 3.77275 | | 1.12193 | | | | | |
| ALA | 71 | 7.795 | 119.034 | 55.464 | 19.316 | | 19.018 | | | | | | | | | | |
| GLN | 72 | 7.582 | 117.638 | 59.099 | 28.559 | 58.752 | 28.704 | 33.889 | | 4.06773 | | 2.13399 | | 2.39276 | | | |
| LYS | 73 | 8.198 | 118.718 | 57.748 | 31.056 | 57.527 | 30.853 | | | 4.11905 | | 1.9299 | | 1.42129 | | 1.16373 | 2.45428 |
| ALA | 74 | 8.247 | 125.013 | 55.55 | 17.988 | | 17.729 | | | 5.05448 | | 1.45125 | | | | | |
| ALA | 75 | 7.904 | 117.944 | 54.747 | 18.507 | 54.649 | 18.262 | | | 4.15769 | | 1.66571 | | | | | |
| GLN | 76 | 7.59 | 116.341 | 56.002 | 29.693 | 55.807 | 29.015 | 34.266 | | 4.39819 | | 2.50602 | | 2.7154 | | | |
| GLY | 77 | 8.277 | 106.739 | 46.292 | -- | 46.194 | | | | 4.10221 | 3.50777 | | | | | | |
| PHE | 78 | 7.801 | 118.747 | 57.862 | 41.505 | 57.417 | 41.246 | | | 4.722 | | 2.66342 | | | | | |
| LEU | 79 | 9.745 | 123.944 | 55.224 | 42.117 | 54.927 | 41.847 | | | 4.61736 | | 2.13382 | | 1.71498 | | 1.12089 | 0.94393 |
| VAL | 80 | 9.822 | 129.925 | 60.731 | 34.566 | 60.488 | 34.356 | | | 5.4048 | | 2.16219 | | 1.03043 | | | |

| | | | | | | | | | | | | | | | | | | | | |
|-----|-----|---------|---------|--------|--------|--------|--------|--------|--------|--------|---------|---------|----------|---------|---------|---------|---------|---------|---------|--|
| ILE | 81 | 9.6 | 126.565 | 56.788 | 40.088 | 56.526 | 39.740 | 28.128 | 17.237 | | 5.36585 | | 1.94094 | | 1.68937 | 1.04515 | 0.78128 | | | |
| ALA | 82 | 9.249 | 129.236 | 49.527 | 21.847 | | 21.595 | | | | 5.4477 | | 1.23719 | | | | | | | |
| GLY | 83 | 9.006 | 106.733 | 46.53 | -- | 46.413 | | | | | | | | | | | | | | |
| LEU | 84 | 8.137 | 122.212 | 55.743 | 46.268 | 55.626 | 46.113 | | | | 4.57225 | | 1.79818 | | 1.25307 | | 0.88434 | 0.7021 | | |
| LYS | 85 | 9.105 | 130.354 | 58.366 | 33.184 | 58.131 | 32.931 | 26.126 | | | 4.64234 | | 1.63949 | | 1.40487 | | 1.05385 | | 2.76264 | |
| GLY | 86 | 8.688 | 108.723 | 43.835 | -- | | | | | | | | | | | | | | | |
| ARG | 87 | 8.07477 | 131.638 | -- | -- | | | | | | 4.3509 | | 1.73781 | | | | 3.24883 | | | |
| THR | 88 | -- | -- | -- | -- | | | | | | | | | | | | | | | |
| TYR | 89 | -- | -- | 57.031 | 40.832 | 57.195 | 40.593 | | | | 4.86314 | | 3.31133 | 3.06416 | | | | | | |
| GLY | 90 | 8.674 | 111.011 | 44.754 | -- | 44.666 | | | | | 4.50977 | 3.87196 | | | | | | | | |
| HIS | 91 | 8.06 | 115.87 | 57.748 | 33.577 | | 33.299 | | | | 4.87675 | | 2.9214 | | | | | | | |
| VAL | 92 | 5.791 | 115.395 | 58.546 | 37.656 | 58.216 | 37.381 | | | | 5.73063 | | 1.90775 | | 0.86316 | 0.66108 | | | | |
| ALA | 93 | 9.267 | 121.566 | 51.427 | 24.519 | 50.548 | 24.239 | | | | 4.85868 | | 1.35962 | | | | | | | |
| VAL | 94 | 9.358 | 122.332 | 62.863 | 34.449 | 62.616 | 34.136 | | | | 4.69736 | | 2.37228 | | 1.08082 | 0.89695 | | | | |
| VAL | 95 | 9.018 | 129.916 | 63.529 | 32.489 | 63.257 | 32.360 | | | | 4.48127 | | 1.99259 | | 1.18665 | 0.98276 | | | | |
| ILE | 96 | 7.787 | 117.645 | 59.294 | 41.46 | 59.092 | 41.357 | | | | 4.88934 | | 2.21985 | | 1.44531 | 1.0209 | 0.75009 | | | |
| SER | 97 | 8.71 | 114.369 | 59.112 | 64.491 | 58.764 | | | | | 4.33343 | | 3.95279 | 3.74295 | | | | | | |
| GLY | 98 | 7.874 | 109.356 | 44.589 | -- | | | | | | | | | | | | | | | |
| PRO | 99 | -- | -- | 63.198 | 32.338 | | 32.085 | 27.386 | | | 4.2756 | | 2.25379 | | 1.89207 | | 3.59609 | | | |
| LEU | 100 | 8.094 | 118.082 | 54.213 | 42.102 | 54.004 | 41.763 | | | | 4.1586 | | 1.6435 | | 1.39482 | | 0.58535 | | | |
| TYR | 101 | 9.197 | 129.032 | 58.404 | 39.137 | | 38.884 | | | | | | | | | | | | | |
| ARG | 102 | -- | -- | 57.129 | -- | 57.063 | | | | 43.292 | 3.67045 | | 1.95628 | 1.59009 | 0.69057 | | 2.91785 | | | |
| GLN | 103 | 7.774 | 106.98 | 58.821 | 27.446 | | | | | | 3.61535 | | 2.27979 | | | | | | | |
| LYS | 104 | 7.327 | 116.413 | -- | -- | | | | | | | | | | | | | | | |
| TYR | 105 | -- | -- | -- | -- | | | | | | | | | | | | | | | |
| PRO | 106 | -- | -- | 63.178 | 34.414 | 62.911 | 34.240 | 27.941 | | | 4.67818 | | 2.1568 | | 1.96814 | | 2.50043 | | | |
| MET | 107 | 9.417 | 120.069 | 54.741 | 30.659 | 54.411 | | | | | 4.68092 | | 1.81988 | | 2.76585 | | | | | |
| CYS | 108 | 8.052 | 110.77 | 56.83 | 34.421 | 56.605 | 34.156 | | | | 6.26065 | | 2.87336 | | | | | | | |
| TRP | 109 | 9.61 | 120.696 | 57.11 | 34.203 | 56.871 | 33.886 | | | | 5.03618 | | 3.60476 | 3.33425 | | | | | | |
| CYS | 110 | 9.415 | 113.804 | 56.993 | 30.946 | | 30.677 | | | | 5.12075 | | 3.41935 | | | | | | | |
| GLY | 111 | 7.737 | 107.733 | 43.575 | -- | 43.146 | | | | | 4.4355 | 3.55262 | | | | | | | | |
| SER | 112 | 8.205 | 107.524 | 59.863 | 65.268 | | | | | | 4.49356 | | 4.07778 | 3.24877 | | | | | | |
| ILE | 113 | 8.955 | 133.45 | 62.513 | 38.58 | 62.351 | 38.302 | 28.938 | 16.218 | 14.162 | 4.14994 | | 1.85346 | | 1.45267 | 1.18735 | 0.75376 | 0.54783 | | |
| ALA | 114 | 8.409 | 124.196 | 52.778 | 18.948 | | 18.677 | | | | 4.10093 | | 1.16481 | | | | | | | |
| GLY | 115 | 7.413 | 105.563 | 44.355 | -- | 44.223 | | | | | 4.25446 | 3.66678 | | | | | | | | |
| ALA | 116 | 8.496 | 124.61 | 55.923 | 18.745 | 56.119 | 18.535 | | | | 3.93664 | | 1.39756 | | | | | | | |
| VAL | 117 | 7.918 | 112.732 | 64.609 | 31.678 | 64.376 | 31.410 | | | | 3.81068 | | 2.02281 | | 0.81251 | | | | | |
| GLY | 118 | 7.562 | 107.192 | 44.571 | -- | 44.506 | | | | | 4.10107 | 3.28174 | | | | | | | | |
| GLN | 119 | 6.977 | 117.521 | 54.728 | 31.268 | 54.422 | | 33.613 | | | 4.34257 | | 2.14151 | | 2.74711 | | | | | |
| SER | 120 | 8.866 | 112.118 | 57.261 | 65.003 | 57.008 | | | | | 4.40856 | | 3.16622 | | | | | | | |
| GLN | 121 | 8.48 | 131.034 | 52.175 | 28.089 | 52.100 | | 33.269 | | | 2.69445 | | -0.00026 | | 0.81986 | | | | | |
| GLY | 122 | 5.981 | 104.739 | 45.651 | -- | | | | | | 3.54682 | 3.01138 | | | | | | | | |

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-------|---------|--------|--------|--------|--------|--------|--|---------|---------|---------|---------|---------|---------|----------|---------|--|
| LEU | 123 | 6.272 | 114.225 | 54.721 | 43.353 | | 42.968 | | | 3.81711 | | 1.56007 | | 1.20945 | | 0.70934 | | |
| LYS | 124 | 7.581 | 117.832 | 54.316 | -- | 54.316 | | | | 4.49136 | | 1.5647 | | 1.19173 | | | | |
| SER | 125 | 8.151 | 113.669 | 56.799 | 67.693 | | 67.349 | | | 4.10652 | | 3.61312 | | | | | | |
| VAL | 126 | 9.397 | 117.672 | 65.012 | 31.237 | 64.760 | 31.089 | | | 4.51251 | | 2.80803 | | 1.30241 | 1.46771 | | | |
| GLY | 127 | 7.96 | 103.673 | 45.842 | -- | 45.580 | | | | 3.78418 | 2.72885 | | | | | | | |
| GLN | 128 | 7.485 | 116.226 | 56.462 | 32.455 | 56.190 | | 35.090 | | 4.43083 | | 1.79036 | 1.25345 | 2.22798 | | | | |
| VAL | 129 | 7.106 | 114.632 | 64.113 | 32.78 | 63.783 | 32.631 | | | 3.94528 | | 1.88867 | | 0.77523 | 0.42237 | | | |
| TRP | 130 | 7.375 | 119.77 | 59.913 | 31.222 | | 31.070 | | | 4.6289 | | 3.15939 | 2.94091 | | | | | |
| ASN | 131 | 9.094 | 116.291 | 52.336 | 38.688 | | | | | | | | | | | | | |
| ARG | 132 | -- | -- | 59.647 | 30.485 | 59.647 | 30.485 | | | 3.69882 | | 1.85689 | | 1.64613 | | 3.21803 | | |
| THR | 133 | 7.879 | 113.89 | 64.751 | 69.186 | 64.384 | | 21.923 | | 4.20772 | | | | 1.20095 | | | | |
| ASP | 134 | 8.595 | 123.629 | 57.154 | 41.066 | | | | | 4.28281 | | 2.56388 | | | | | | |
| ARG | 135 | 8.505 | 114.648 | 58.693 | 29.274 | 58.434 | 29.223 | | | 3.64535 | | 1.83315 | | 1.46152 | | 2.64322 | | |
| ASP | 136 | 7.182 | 117.118 | 55.297 | 41.449 | | | | | 5.24888 | | 3.12372 | 2.53614 | | | | | |
| ARG | 137 | 7.885 | 119.436 | 55.311 | 31.028 | 55.098 | | 43.765 | | 4.56841 | | 1.89373 | | 1.64485 | | 3.22938 | | |
| LEU | 138 | 6.234 | 115.501 | 55.605 | 42.805 | 55.288 | 42.552 | | | 3.38678 | | 1.07475 | | 0.18509 | | -1.07008 | | |
| ASN | 139 | 7.068 | 116.088 | 51.739 | 43.582 | | | | | 4.68121 | | 2.60922 | 1.74593 | | | | | |
| TYR | 140 | 8.645 | 119.17 | 56.923 | 41.79 | 56.565 | 41.515 | | | 5.05283 | | 2.59112 | 2.39688 | | | | | |
| TYR | 141 | 9.452 | 123.016 | 56.79 | 42.347 | 56.672 | 42.139 | | | 5.55639 | | 3.22528 | 2.78493 | | | | | |
| VAL | 142 | 9.492 | 122.153 | 58.914 | 36.505 | 58.719 | 36.242 | | | 5.72828 | | 1.79202 | | 1.06855 | 0.79661 | | | |
| TYR | 143 | 7.816 | 129.667 | 58.023 | 37.387 | | | | | 5.35775 | | 3.31256 | | | | | | |
| SER | 144 | 8.397 | 118.6 | -- | 63.451 | | | | | 3.88587 | | 3.51897 | | | | | | |
| LEU | 145 | 6.377 | 120.425 | 53.739 | 45.673 | | | | | 4.58963 | | 1.46184 | | 0.8526 | | | | |
| ALA | 146 | 8.36 | 125.723 | 53.263 | 17.813 | | 17.534 | | | 3.06241 | | 0.61941 | | | | | | |
| SER | 147 | 8.403 | 119.781 | 61.406 | 65.568 | 61.180 | | | | 4.57994 | | 3.89997 | 3.49345 | | | | | |
| CYS | 148 | 7.931 | 118.222 | 52.872 | 38.352 | 52.821 | 38.154 | | | 5.06153 | | 3.76573 | 3.14869 | | | | | |
| SER | 149 | 8.352 | 115.443 | 57.906 | 65.347 | 57.468 | | | | 4.51948 | | 3.76201 | | | | | | |
| LEU | 150 | 8.283 | 124.408 | 53.553 | 42.246 | | | | | | | | | | | | | |
| PRO | 151 | -- | -- | 63.465 | -- | 63.212 | | 50.764 | | 4.4233 | | 2.28373 | | 1.94249 | | 3.87214 | 3.64175 | |
| ARG | 152 | 8.394 | 121.773 | 56.285 | 31.299 | | | | | 4.30108 | | 1.85722 | 1.65319 | 1.39821 | | 3.21038 | | |
| ALA | 153 | 8.003 | 131.465 | -- | -- | | | | | 4.36314 | | 1.40854 | | | | | | |
| SER | 154 | 7.929 | 121.011 | -- | -- | | | | | | | | | | | | | |
| LEU | 155 | -- | -- | -- | -- | | | | | | | | | | | | | |
| GLU | 156 | -- | -- | -- | -- | | | | | | | | | | | | | |
| HIS | 157 | -- | -- | -- | -- | | | | | | | | | | | | | |
| HIS | 158 | -- | -- | -- | -- | | | | | | | | | | | | | |
| HIS | 159 | -- | -- | -- | -- | | | | | | | | | | | | | |
| HIS | 160 | -- | -- | -- | -- | | | | | | | | | | | | | |
| HIS | 161 | -- | -- | -- | -- | | | | | | | | | | | | | |
| HIS | 162 | -- | -- | -- | -- | | | | | | | | | | | | | |

Appendix 2: Residue Assignment for Tae1 in HCCH COSY and HCCH TOCSY Experiments


| Residue # | | HCCH COSY Assignments | | | | | | | | | | HCCH TOCSY Assignments | | | | | | | | | |
|-----------|----------|-----------------------|-------|-------|--------|-------|-------|--------|--------|-------|------|------------------------|-------|-------|-------|-------|-------|--------|--------|-------|------|
| | | Ha1 | Ha2 | Hb1 | Hb2 | Hg1 | Hg2 | HCD1 | HCD2 | HCE1 | HCE2 | Ha1 | Ha2 | Hb1 | Hb2 | Hg1 | Hg2 | HCD1 | HCD2 | HCE1 | HCE2 |
| 1 | met | | | | | | | | | | | | | | | | | | | | |
| 2 | asp | 4.563 | | | 2.640 | | | | | | | 4.714 | | 2.747 | 2.569 | | | | | | |
| 3 | ser | 4.577 | | | 3.956 | | | | | | | 4.579 | | 3.953 | | | | | | | |
| 4 | leu | 3.367 | | | -0.227 | 0.943 | | -0.041 | -0.036 | | | 3.367 | | 0.757 | | 0.957 | | -0.039 | -0.039 | | |
| 5 | asp | 3.620 | | 2.267 | | | | | | | | 4.604 | | 3.300 | 3.073 | | | | | | |
| 6 | gln | 3.838 | | 2.340 | | 2.350 | | | | | | 3.826 | | 2.041 | | 2.425 | | | | | |
| 7 | cys | 4.660 | | 3.442 | 3.003 | | | | | | | 3.642 | | 2.263 | | | | | | | |
| 8 | ile | 3.762 | | 2.110 | | 1.116 | 0.928 | | | | | 3.743 | | 2.132 | | 1.108 | 0.935 | | | | |
| 9 | val | 3.115 | | 2.026 | | 1.059 | | | | | | 3.104 | | 2.035 | | 1.053 | | | | | |
| 10 | asn | 4.281 | | 2.734 | | | | | | | | | | | | | | | | | |
| 11 | ala | 3.903 | | 1.316 | | | | | | | | 3.896 | | 1.270 | | | | | | | |
| 12 | cys | | | | | | | | | | | | | | | | | | | | |
| 13 | lys | 4.307 | | 0.958 | | 0.917 | | 1.418 | | 2.885 | | 4.298 | | 0.888 | 0.216 | 0.853 | | 1.420 | | 2.885 | |
| 14 | asn | 4.555 | | 2.995 | 2.782 | | | | | | | 4.538 | | 2.978 | | 2.759 | | | | | |
| 15 | ser | 4.445 | | 3.852 | | | | | | | | 4.463 | | 3.846 | | | | | | | |
| 16 | trp | | | | | | | | | | | | | | | | | | | | |
| 17 | asp | 4.854 | | 3.106 | 2.652 | | | | | | | 4.866 | | 2.993 | 2.624 | | | | | | |
| 18 | lys | 3.749 | | 1.805 | | 1.536 | | 1.718 | | 2.989 | | 3.745 | | 1.816 | | 1.536 | | 1.722 | | 3.033 | |
| 19 | ser | 4.546 | | | 3.628 | | | | | | | 4.541 | | 3.612 | | | | | | | |
| 20 | tyr | 3.846 | | 2.426 | | | | | | | | 3.813 | | 2.444 | | | | | | | |
| 21 | leu | | | | | | | 0.310 | | | | | | | | | | 0.310 | | | |
| 22 | ala | 3.889 | | 1.275 | | | | | | | | 3.888 | | 1.270 | | | | | | | |
| 23 | gly | 4.177 | 3.686 | | | | | | | | | 4.200 | 3.682 | | | | | | | | |
| 24 | thr | | | | | | | | | | | | | | | | | | | | |
| 25 | pro | | | | | | | | | | | | | | | | | | | | |
| 26 | asn | 4.412 | | 2.811 | | | | | | | | 4.419 | | 2.814 | | | | | | | |
| 27 | lys | | | | | | | | | | | | | | | | | | | | |
| 28 | asp | 4.949 | | | | | | | | | | 4.913 | | | | | | | | | |
| 29 | asn | 5.054 | | 3.768 | 3.177 | | | | | | | 5.055 | | 3.708 | 3.144 | | | | | | |
| 30 | cys30ala | | | | | | | | | | | 4.250 | | 3.177 | | | | | | | |
| 31 | ser | 4.965 | | 4.077 | | | | | | | | 4.940 | | 4.077 | | | | | | | |
| 32 | gly | | | | | | | | | | | 3.702 | 3.545 | | | | | | | | |
| 33 | phe | 4.672 | | 2.326 | | | | | | | | 4.660 | | 2.442 | | | | | | | |
| 34 | val | | | | | | | | | | | | | | | | | | | | |
| 35 | gln | | | | | | | | | | | | | | | | | | | | |
| 36 | ser | 4.129 | | | 3.841 | | | | | | | 4.151 | | 3.845 | | | | | | | |
| 37 | val | 3.060* | | 1.818 | | 0.083 | | | | | | 3.093 | | 1.807 | | 0.721 | | | | | |

| | | | | | | | | | | | | | | | | | | | | |
|----|-----|---------|-------|--------|--------|---------|---------|--------|--------|-------|--------|-------|--------|-------|--------|--------|--------|-------|-------|-------|
| 38 | ala | 3.942 | | 1.394 | | | | | | | 3.945 | | 1.394 | | | | | | | |
| 39 | ala | 4.124 | | 1.542 | | | | | | | 4.119 | | 1.540 | | | | | | | |
| 40 | glu | 4.038 | | | 2.150 | 2.618? | 2.572? | | | | 3.960 | | 2.252 | 1.993 | 2.112 | 2.097 | | | | |
| 41 | leu | 4.330 | | 1.505 | | 1.513 | | 0.689 | | | 4.332 | | 1.478 | | 1.193 | | 0.703 | | | |
| 42 | gly | | | | | | | | | | 3.989 | 3.743 | | | | | | | | |
| 43 | val | 3.952 | | 1.503 | | 0.168 | | | | | 3.935 | | 1.499 | | 0.168 | 0.168 | | | | |
| 44 | pro | 4.4175 | | 2.278 | 1.8851 | 2.0113 | | 3.846 | 3.6388 | | 4.4806 | | 2.2833 | | 2.0288 | | 3.8486 | | | |
| 45 | met | | | | | | | | | | 5.257 | | 1.872 | 1.657 | 1.872 | 1.667 | | | | |
| 46 | pro | 4.3288 | | 2.278 | 1.6326 | 1.6369 | | 3.6171 | 3.4745 | | 4.2554 | | 2.2929 | | 1.7237 | | 3.6222 | | | |
| 47 | arg | 4.230 | | 1.679 | | 1.649 | | 3.193 | | | 4.236 | | 1.747 | | 1.678 | | 3.198 | | | |
| 48 | gly | 4.383 | 3.629 | | | | | | | | 4.241 | 3.661 | | | | | | | | |
| 49 | asn | | | | | | | | | | | | 2.723 | | | | | | | |
| 50 | ala | 4.235 | | 1.669 | | | | | | | 4.240 | | 1.653 | | | | | | | |
| 51 | asn | | | | | | | | | | 4.262 | | 2.714 | | | | | | | |
| 52 | ala | 4.134 | | 1.505 | | | | | | | 4.341 | | 1.443 | | | | | | | |
| 53 | met | 3.434 | | 1.955 | 1.666 | 2.245 | 2.010 | | | | 3.441 | | 1.999 | 1.697 | 2.048 | 1.886 | | | | |
| 54 | val | 3.1929* | | 2.009 | | | | | | | 3.078 | | 2.015 | | 0.819 | | | | | |
| 55 | asp | 4.611 | | 3.043 | | | | | | | 4.310 | | 2.708 | 2.541 | | | | | | |
| 56 | gly | 3.893 | 3.387 | | | | | | | | 3.866 | 3.402 | | | | | | | | |
| 57 | leu | | | | | 1.661 | | 0.689 | | | | | | | | | | | | |
| 58 | glu | 3.9185 | | 1.9856 | | 2.2586 | | | | | 3.9328 | | 1.9867 | | 2.3029 | 2.1686 | | | | |
| 59 | gln | 4.292 | | 2.189 | 2.196 | 2.5341* | 2.5341* | | | | 4.285 | | 2.246 | 2.139 | 2.522 | | | | | |
| 60 | ser | | | | | | | | | | 4.228 | | 3.828 | | | | | | | |
| 61 | trp | | | | | | | | | | 4.070 | | 2.458 | 2.347 | | | | | | |
| 62 | thr | 4.276 | | 4.057 | | 1.149 | | | | | 4.261 | | 4.057 | | 1.125 | | | | | |
| 63 | lys | 5.100 | | 1.780 | | 1.379 | | | | | 5.112 | 1.775 | | 1.353 | | 1.780 | | 3.030 | | |
| 64 | leu | | | | | | | | | | 4.575 | | 1.567 | | 0.668 | | 0.753 | 0.753 | | |
| 65 | ala | 4.344 | | 1.469 | | | | | | | 4.340 | | 1.452 | | | | | | | |
| 66 | ser | | | | | | | | | | | | | | | | | | | |
| 67 | gly | 3.583 | 2.693 | | | | | | | | 3.573 | 2.680 | | | | | | | | |
| 68 | ala | 4.649 | | 1.668 | | | | | | | 4.560 | | 1.645 | | | | | | | |
| 69 | glu | 3.967 | | 1.790 | | 1.831 | | | | | 3.964 | | 1.384 | | 1.812 | | | | | |
| 70 | ala | 3.787 | | 1.566 | | | | | | | 3.812 | | 1.558 | | | | | | | |
| 71 | ala | 3.770 | | 1.117 | | | | | | | 3.779 | | 1.112 | | | | | | | |
| 72 | gln | | | | | | | | | | | | | | | | | | | |
| 73 | lys | 4.127 | | 1.950 | | 1.441 | 1.100 | 1.439 | 0.932 | 2.488 | 2.173 | 4.121 | 1.937 | 1.407 | 1.483 | 1.622 | 1.408 | 0.949 | 2.485 | 2.175 |
| 74 | ala | 3.997 | | 1.2822 | | | | | | | 3.967 | | 1.268 | | | | | | | |
| 75 | ala | 4.178 | | 1.664 | | | | | | | 4.164 | | 1.657 | | | | | | | |
| 76 | gln | 4.371 | | 2.018 | 2.043 | 2.348 | | | | | 4.314 | | | | | | | | | |
| 77 | gly | | 3.481 | | | | | | | | 4.084 | 3.498 | | | | | | | | |
| 78 | phe | 4.872 | | 2.971 | | | | | | | 4.867 | | 2.950 | | | | | | | |
| 79 | leu | 4.284 | | 1.573 | | 1.498 | | 0.839 | | | 4.294 | | 1.570 | | 1.480 | | 0.928 | 0.925 | | |


| | | | | | | | | | | | | | | | | | | | | | |
|-----|-----|--------|-------|--------|--------|--------|-------|--------|--|-------|--|--------|-------|--------|-------|--------|--------|--------|-------|-------|-------|
| 80 | val | | | 2.286 | | 0.953 | | | | | | | | 2.337 | | 1.073 | | | | | |
| 81 | ile | 5.367 | | 1.931 | | 1.688 | 0.753 | 0.771 | | | | 5.362 | | 1.915 | | 1.670 | 0.768 | 0.781 | | | |
| 82 | ala | | | | | | | | | | | | | | | | | | | | |
| 83 | gly | 5.334 | 3.701 | | | | | | | | | 5.359 | 3.655 | | | | | | | | |
| 84 | leu | 4.548 | | | | 1.795 | | 0.839 | | | | 4.578 | | 1.805 | | 1.757 | | 0.836 | 0.836 | | |
| 85 | lys | | | | | | | | | | | | | | | | | | | | |
| 86 | gly | 4.582 | 3.681 | | | | | | | | | 4.589 | 3.730 | | | | | | | | |
| 87 | arg | 3.980 | | 1.831 | | 1.630 | | | | | | | | | | | | | | | |
| 88 | thr | 4.217 | | 3.920 | | | | | | | | 4.215 | | 3.957 | | 0.994 | | | | | |
| 89 | tyr | | | | | | | | | | | | | | | | | | | | |
| 90 | gly | 4.380 | 3.718 | | | | | | | | | 4.589 | 3.934 | | | | | | | | |
| 91 | his | | | | | | | | | | | 4.383 | | 3.929 | | | | | | | |
| 92 | val | 5.7548 | | 1.9246 | | 0.8389 | | | | | | 5.7259 | | 1.89 | | 0.8656 | 0.8656 | | | | |
| 93 | ala | | | | | | | | | | | | | | | | | | | | |
| 94 | val | 4.088 | | 2.017 | | 0.845 | | | | | | 4.058 | | 2.023 | | | | | | | |
| 95 | val | 3.965 | | 2.026 | | 0.836 | | | | | | | | | | | | | | | |
| 96 | ile | 4.897 | | 2.124 | | 1.405 | | 1.104 | | | | 4.885 | | 2.219 | | 1.470 | | 1.105 | | | |
| 97 | ser | 4.389 | | | | 3.845 | | | | | | 4.397 | | 3.850 | | | | | | | |
| 98 | gly | 4.136 | 3.300 | | | | | | | | | 4.451 | | | | | | | | | |
| 99 | pro | 4.4175 | | 2.2781 | 1.8885 | 2.0164 | | 3.6027 | | | | 4.2559 | | 2.2747 | | 2.1239 | | 3.6207 | | | |
| 100 | leu | | | | | | | | | | | 4.176 | | 1.396 | | 0.608 | | 0.463 | 0.463 | | |
| 101 | tyr | | | | | | | | | | | 4.588 | | 3.957 | | | | | | | |
| 102 | arg | | | | | | | | | | | | | | | | | | | | |
| 103 | gln | 4.657 | | 1.398 | | 1.382 | | | | | | 4.649 | | 1.658 | | 1.445 | | | | | |
| 104 | lys | 4.307 | | 0.669 | | 0.737 | | 1.661 | | 2.885 | | 4.291 | | 0.796 | 0.662 | 0.974 | 0.756 | 1.412 | 1.422 | 2.882 | 2.733 |
| 105 | tyr | 4.262 | | 2.679 | | | | | | | | 4.221 | | 2.727 | | | | | | | |
| 106 | pro | | | | | | | | | | | | | | | | | | | | |
| 107 | met | | | | | | | | | | | 4.035 | | 2.093 | | 2.500 | | | | | |
| 108 | cys | 4.448 | | 3.175 | 3.175 | | | | | | | 4.398 | | 2.720 | 2.502 | | | | | | |
| 109 | trp | 4.564 | | 2.979 | | | | | | | | 4.552 | | 2.999 | | | | | | | |
| 110 | cys | | | | | | | | | | | 4.566 | | 3.178 | 3.041 | | | | | | |
| 111 | gly | 4.427 | 3.497 | | | | | | | | | 4.441 | 3.557 | | | | | | | | |
| 112 | ser | 4.581 | | | | 3.808 | | | | | | 4.397 | | 3.857 | | | | | | | |
| 113 | ile | 4.129 | | 1.831 | | 1.423 | | 0.783 | | | | 4.141 | | 1.865 | | 1.185 | 1.416 | 0.794 | | 0.777 | |
| 114 | ala | 4.104 | | 1.163 | | | | | | | | | | 1.610 | | | | | | | |
| 115 | gly | 4.415 | 3.660 | | | | | | | | | 4.410 | 3.664 | | | | | | | | |
| 116 | ala | 4.217 | | 1.439 | | | | | | | | 4.251 | | 1.465 | | | | | | | |
| 117 | val | 3.797 | | 1.993 | | 0.838 | | | | | | 3.816 | | 2.024 | | 0.780 | | | | | |
| 118 | gly | 4.415 | 3.730 | | | | | | | | | 4.097 | 3.284 | | | | | | | | |
| 119 | gln | 4.728 | | | | | | | | | | 4.033 | | 2.601 | | 2.124 | | | | | |
| 120 | ser | 4.495 | | | | 3.783 | | | | | | 4.517 | | 3.757 | | | | | | | |
| 121 | gln | 3.807 | | 2.026 | | 2.378 | | | | | | 3.793 | | 1.793 | | 2.303 | | | | | |

| | | | | | | | | | | | | | | | | | | | | |
|-----|-----|--------|-------|--------|-------|--------|--|--------|--|--|--|--------|--------|-------|--------|-------|--------|--|--|--|
| 122 | gly | | | | | | | | | | | | | | | | | | | |
| 123 | leu | 4.3409 | | 1.3647 | | 1.2076 | | 0.7288 | | | | 4.322 | 1.4941 | | 1.1999 | | 0.7278 | | | |
| 124 | lys | | | | | | | | | | | | | | | | | | | |
| 125 | ser | 5.320 | | | 4.089 | | | | | | | 5.321 | 4.117 | | | | | | | |
| 126 | val | | | | | | | | | | | | | | | | | | | |
| 127 | gly | 4.195 | 3.672 | | | | | | | | | 3.523 | 3.002 | | | | | | | |
| 128 | gln | | | | | | | | | | | | | | | | | | | |
| 129 | val | 3.937 | | 1.857 | | 0.732 | | | | | | 3.963 | 1.882 | | 0.431 | 0.821 | | | | |
| 130 | trp | | | | | | | | | | | 4.504 | 3.008 | | | | | | | |
| 131 | asn | 4.417 | | 3.392 | 2.840 | | | | | | | 4.406 | 3.422 | | | | | | | |
| 132 | arg | 3.702 | | 1.846 | | 1.617 | | 3.193 | | | | 3.705 | 1.853 | 1.848 | 1.564 | | 3.202 | | | |
| 133 | thr | 4.255 | | 4.169 | | | | | | | | 4.223 | 3.934 | | 1.199 | | | | | |
| 134 | asp | 4.255 | | 2.605 | | | | | | | | 4.282 | 2.666 | 2.562 | | | | | | |
| 135 | arg | | | | | | | | | | | | | | | | | | | |
| 136 | asp | 4.485 | | 1.520 | | | | | | | | 4.227 | 3.199 | | | | | | | |
| 137 | arg | 4.612 | | | 3.141 | | | | | | | | | | | | | | | |
| 138 | leu | 3.3957 | | 1.0169 | | 0.1513 | | -1.042 | | | | 3.3847 | 1.1137 | | 0.1607 | | -1.081 | | | |
| 139 | asn | | | | | | | | | | | | | | | | | | | |
| 140 | tyr | | | | | | | | | | | | | | | | | | | |
| 141 | tyr | | | | | | | | | | | | | | | | | | | |
| 142 | val | | | | | | | | | | | | | | | | | | | |
| 143 | tyr | 4.157 | | 2.169 | | | | | | | | 4.162 | 2.149 | | | | | | | |
| 144 | ser | | | | | | | | | | | | | | | | | | | |
| 145 | leu | | | | | | | | | | | | | | | | | | | |
| 146 | ala | | | | | | | | | | | | | | | | | | | |
| 147 | ser | | | | | | | | | | | 4.566 | 3.963 | | | | | | | |
| 148 | cys | | | 2.998 | 2.754 | | | | | | | 2.976 | 2.748 | | | | | | | |
| 149 | ser | 4.384 | | 3.852 | | | | | | | | 4.396 | 3.853 | | | | | | | |
| 150 | leu | | | | | | | | | | | | | | | | | | | |
| 151 | pro | | | | | | | | | | | | | | | | | | | |
| 152 | arg | | | | | | | | | | | | | | | | | | | |
| 153 | ala | 4.286 | | 1.379 | | | | | | | | | | | | | | | | |
| 154 | ser | 4.393 | | | 3.845 | | | | | | | | | | | | | | | |


Appendix 3: NHC Experiment with Assignments Shown



Appendix 5: Graphical Comparison of NMR (NHSQC) peak intensity of WT-Tae1 Titration with Hcp1



Appendix 6: Graphical Comparison of NMR (NHSQC) peak intensity of Tae1-S115Q Titration with Hcp1



Appendix 7: Experimental Design for Confirmation of Tae1 Minimal Binding Fragment Specificity

